Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.30 |
| ▸ | EEF2K | O00418 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | CLK2 | P49760 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | PRKX | P51817 | 1/20 | 0.30 |
| ▸ | NEK4 | P51957 | 1/20 | 0.30 |
| ▸ | PRKG2 | Q13237 | 1/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.30 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.30 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.30 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.30 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29908237 | 0.90 | ROCK2 (0.32) | ROCK2 | |
| SCHEMBL29627918 | 0.89 | — | — | |
| SCHEMBL29627919 | 0.84 | ROCK2 (0.37) | ROCK2EEF2KMAP4K4CLK2GSK3B | |
| SCHEMBL29627966 | 0.83 | EIF2AK4 (0.34) | ROCK2 | |
| SCHEMBL29908228 | 0.82 | LRRK2 (0.33) | ROCK2 | |
| SCHEMBL29640848 | 0.82 | ROCK2 (0.38) | ROCK2ROCK1 | |
| SCHEMBL26289777 | 0.79 | ROCK2 (0.35) | ROCK2EEF2KMAP4K4CLK2GSK3B | |
| SCHEMBL25195353 | 0.77 | ROCK2 (0.38) | ROCK2EEF2KMAP4K4CLK2GSK3B | |
| SCHEMBL29640830 | 0.77 | ROCK2 (0.38) | ROCK2EEF2KMAP4K4CLK2GSK3B | |
| SCHEMBL29627860 | 0.77 | ROCK2 (0.38) | ROCK2EEF2KMAP4K4CLK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220281841-A1 | ETHYNYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ANGION BIOMEDICA CORP. | 2022-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281841-A1 | ETHYNYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ROCK1, ROCK2, CIT | ROCK2 2/4885EEF2K 186/4885MAP4K4 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.